DE60032905D1 - Selektive iglur5 rezeptorantagonisten zur behandlung der migräne - Google Patents

Selektive iglur5 rezeptorantagonisten zur behandlung der migräne

Info

Publication number
DE60032905D1
DE60032905D1 DE60032905T DE60032905T DE60032905D1 DE 60032905 D1 DE60032905 D1 DE 60032905D1 DE 60032905 T DE60032905 T DE 60032905T DE 60032905 T DE60032905 T DE 60032905T DE 60032905 D1 DE60032905 D1 DE 60032905D1
Authority
DE
Germany
Prior art keywords
migraine
treatment
receptor antagonists
iglur5 receptor
selective iglur5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60032905T
Other languages
English (en)
Other versions
DE60032905T2 (de
Inventor
David Bleakman
Amy Suzon Chappell
Ann Filla
Willis Johnson
Leslie Ornstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60032905D1 publication Critical patent/DE60032905D1/de
Publication of DE60032905T2 publication Critical patent/DE60032905T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60032905T 1999-07-06 2000-06-27 Selektive iglur5 rezeptorantagonisten zur behandlung der migräne Expired - Lifetime DE60032905T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14248599P 1999-07-06 1999-07-06
US142485P 1999-07-06
US15116599P 1999-08-27 1999-08-27
US151165P 1999-08-27
PCT/US2000/016297 WO2001001972A2 (en) 1999-07-06 2000-06-27 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE

Publications (2)

Publication Number Publication Date
DE60032905D1 true DE60032905D1 (de) 2007-02-22
DE60032905T2 DE60032905T2 (de) 2007-10-18

Family

ID=26840135

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60032905T Expired - Lifetime DE60032905T2 (de) 1999-07-06 2000-06-27 Selektive iglur5 rezeptorantagonisten zur behandlung der migräne

Country Status (28)

Country Link
US (4) US6566370B1 (de)
EP (1) EP1200073B1 (de)
JP (1) JP4619595B2 (de)
KR (1) KR20020024300A (de)
CN (1) CN1230174C (de)
AR (1) AR029373A1 (de)
AU (1) AU773304B2 (de)
BR (1) BR0012175A (de)
CA (1) CA2378613C (de)
CZ (1) CZ20014488A3 (de)
DE (1) DE60032905T2 (de)
DK (1) DK1200073T3 (de)
DZ (1) DZ3209A1 (de)
EA (1) EA004290B1 (de)
ES (1) ES2278619T3 (de)
HK (1) HK1047036A1 (de)
HR (1) HRP20020013A2 (de)
HU (1) HUP0202253A3 (de)
IL (1) IL146697A0 (de)
MX (1) MXPA01012726A (de)
MY (1) MY133503A (de)
NO (1) NO20016246L (de)
NZ (1) NZ515616A (de)
PE (1) PE20010299A1 (de)
PT (1) PT1200073E (de)
SK (1) SK112002A3 (de)
TR (1) TR200200066T2 (de)
WO (1) WO2001001972A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257545A1 (de) 1999-12-22 2002-11-20 Eli Lilly And Company Selektive iglur5 rezeptor antagonisten
AU2002241565A1 (en) * 2001-01-05 2002-07-16 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
WO2002053561A1 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
BR0116724A (pt) * 2001-01-05 2004-01-27 Lilly Co Eli Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto
US7205313B2 (en) 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6953805B2 (en) 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6924294B2 (en) 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6855725B2 (en) * 2001-01-05 2005-02-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US20040082606A1 (en) * 2001-12-20 2004-04-29 Khau Vien Van Excitatory amino acid receptor antagonists
PT1511741E (pt) 2002-04-26 2013-02-05 Lilly Co Eli Derivados éster de um ácido deca-hidroisoquinolino-3- carboxílico como analgésicos
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (de) 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
JP7399096B2 (ja) 2018-03-05 2023-12-15 ヤンセン ファーマシューティカ エヌ．ベー． 神経変性を検出するためのアッセイ
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
PH12022551110A1 (en) 2019-11-08 2024-02-26 Xenon Pharmaceuticals Inc Methods of treating depressive disorders
WO2022173855A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
CN1259126A (zh) * 1997-04-07 2000-07-05 伊莱利利公司 药物
ATE240299T1 (de) 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure

Also Published As

Publication number Publication date
US20050159445A1 (en) 2005-07-21
CZ20014488A3 (cs) 2003-01-15
PT1200073E (pt) 2007-03-30
EP1200073A2 (de) 2002-05-02
AU5873200A (en) 2001-01-22
PE20010299A1 (es) 2001-03-07
IL146697A0 (en) 2002-07-25
MY133503A (en) 2007-11-30
TR200200066T2 (tr) 2002-04-22
WO2001001972A3 (en) 2001-12-06
AR029373A1 (es) 2003-06-25
US7157582B2 (en) 2007-01-02
AU773304B2 (en) 2004-05-20
BR0012175A (pt) 2002-03-05
MXPA01012726A (es) 2002-07-02
US20030199546A1 (en) 2003-10-23
SK112002A3 (en) 2003-05-02
EA004290B1 (ru) 2004-02-26
DZ3209A1 (fr) 2001-01-11
HUP0202253A3 (en) 2003-12-29
DE60032905T2 (de) 2007-10-18
JP4619595B2 (ja) 2011-01-26
NO20016246L (no) 2002-03-04
HRP20020013A2 (en) 2003-08-31
HUP0202253A2 (hu) 2002-11-28
DK1200073T3 (da) 2007-05-07
NO20016246D0 (no) 2001-12-19
WO2001001972A2 (en) 2001-01-11
CN1230174C (zh) 2005-12-07
CN1359289A (zh) 2002-07-17
EA200200132A1 (ru) 2002-06-27
CA2378613A1 (en) 2001-01-11
NZ515616A (en) 2004-05-28
US6566370B1 (en) 2003-05-20
EP1200073B1 (de) 2007-01-10
US6855823B2 (en) 2005-02-15
JP2003503449A (ja) 2003-01-28
US6759418B2 (en) 2004-07-06
KR20020024300A (ko) 2002-03-29
HK1047036A1 (zh) 2003-02-07
ES2278619T3 (es) 2007-08-16
US20040192722A1 (en) 2004-09-30
CA2378613C (en) 2007-10-02

Similar Documents

Publication Publication Date Title
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60005471D1 (de) EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose
NO20032360D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE266655T1 (de) Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60022917D1 (de) Reboxetin zur Behandlung von Migränekopfschmerzen
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
EP1156792A4 (de) Methoden und zusammenstellungen zur behandlung des reizdarmsyndroms unter verwendung von niedrigdosierten antagonisten des opioidrezeptors
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
ATE304530T1 (de) Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen
ATE370728T1 (de) Antagonisten des gardos-kanals
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE50009813D1 (de) Kombinationpräparat zur behandlung von sexueller dysfunktion
DE60016769D1 (de) Antagonisten des vitronectin-receptors
NO20052012L (no) Indoler nyttige for behadling av androgen-reseptor relaterte sykdommer
ATE280156T1 (de) Phthalimido arylpiperazinen als alpha 1a rezeptor antagonisten nützlich zur behandlung von gutartigen prostatahyperplasia
ATE335500T1 (de) Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN